Effects of different forms of coconut on lipid profile

Recruitment status	Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
08/09/2023 Completed	[X] Results
Condition category	[] Individual participant data
	No longer recruiting Overall study status Completed

Plain English summary of protocol

Background and study aims

The contribution of dietary fat intake towards atherosclerosis (narrowing of the arteries) is currently generating much debate and a clear association between dietary saturated fat and ischemic events including death has not been established so far. Foods consumed by the general populace are complex and would not contain fatty acids or any other nutrient in isolation and different saturated and unsaturated fatty acids could possibly give rise to different effects on lipid chemistry. Hence the clinically relevant effects of saturated fats derived from different origins could well be different. It is found that coconut fats account for about 80% of the fat intake among Sri Lankans of which 92% consists of saturated fats. Some say that coconut fat may increase the risk of ischemic heart disease among Sri Lankans. However, since saturated fats in coconut are medium-chain fatty acids and do not undergo degradation and re-esterification processes, the hypothesis that coconut fat is bad for health may be questionable. Although coconut oil increases HDL levels, no clear evidence exists to date to claim that coconut oil reduces the risk of atherosclerotic heart disease. As coconut milk contains a significant argininerich protein content and also soluble fiber, the lipid effects may be compounded by these dietary elements as well and the effect observed on the lipid profile may not be entirely due to the fatty acids. Coconut is consumed by the vast majority of people in many Asian countries. It is therefore important to investigate the relationship between the lipid profile and coconut consumption. The aim of this study is to investigate the lipid effects of different forms of coconut, i.e., oil, milk, and flakes, when consumed by free-living healthy subjects.

Who can participate? Healthy volunteers aged 25-60 years

What does the study involve?

The participants are randomly allocated to one of three dietary supplementations: coconut milk powder (30 g), grated coconut (30 g) or coconut oil (30 ml), or a control group (no supplementation). The coconut supplements had different calorie, fat, fiber, and protein content. Participants are instructed to take the allocated supplement for 4 weeks and maintain a daily dietary diary to ensure that their diet does not vary significantly. Body Mass Index (BMI), lipid profile, fasting blood sugar (FBS) and HbA1c are measured three times (baseline and after 4 and 8 weeks).

What are the possible benefits and risks of participating? There are not any significant health risks or any other risks associated with this study. The results could help raise awareness of the effects of different forms of coconut on the liver.

Where is the study run from? Medical Research Institute, Colombo (Sri Lanka)

When is the study starting and how long it is expected to run for? April 2013 to June 2017

Who is funding the study? Investigator initiated and funded

Who is the main contact?

Dr Ruvan Ekanayake, Ruvan_nishali.ekanayaka@yahoo.com

Contact information

Type(s)

Principal Investigator

Contact name

Dr Ruvan Ekanayaka

Contact details

Nawaloka Hospitals PLC Colombo Sri Lanka 00200 +94 (0)714357889/+94 (0)777248084 Ruvan_nishali.ekanayaka@yahoo.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CLPRCT2

Study information

Scientific Title

Effect of different forms of coconut on the lipid profiles of healthy free-living Sri Lankan subjects

Acronym

ECLPSL

Study objectives

Different forms of coconut preparations have different effects on lipid profile

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 18/03/2014, Ethics Review Committee, Medical Research Institute (PO Box 527, Sir Danister de Silva Mawatha, Colombo 8, 00900, Sri Lanka; +94 (0)112693532; ethicsmri@gmail. com), ref: 02/2016 (Project number 43/2013)

Study design

Single-centre interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Workplace

Study type(s)

Treatment, Efficacy

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Lipid profile

Interventions

A randomized, placebo-controlled, prospective clinical trial was conducted at the Institute of Medical Research (MRI), Colombo, Sri Lanka. Participants were recruited from a local advertisement displayed in the Medical Research Institute, Colombo, Sri Lanka. A comprehensive medical history was obtained, and a physical examination of the subjects who volunteered was done before recruiting. A random number between 1 and 4, taken from a table of random numbers, was assigned to each consented participant. The participants were randomly allocated to one of three dietary supplementation regimens: coconut milk powder 30 g, grated coconut 30 g or coconut oil 30 ml, or the control group. The coconut supplements were not equi-caloric and had different fat, fiber, and protein content. Each participant was instructed to take the allocated supplement for 4 weeks and was asked to maintain a daily dietary diary to ensure that the diet did not vary significantly. Fasting Blood Sugar (FBS) and HbA1c were measured three times: i.e., baseline, after 4 weeks and 8 weeks. BMI was measured by a single research assistant and all laboratory tests were done by a single technician. Lipid profiles were done after 10 hours of mandatory fasting and FBS was done after 8 hours fast. Total cholesterol, HDL-cholesterol

and triglyceride concentrations were measured in serum by a Roch/Hitachi Modular P Chemistry Analyzer (Mod P). The cholesterol assay used the cholesterol oxidase/peroxidase (CHOD/POD) method. HDL cholesterol was measured by a direct non-precipitating method using polyethylene glycol-coupled cholesteryl esterase (PEG-modified enzyme) and cholesterol oxidase. Triglycerides were analyzed using the glycerokinase/glycerophosphate oxidase method after initial hydrolysis with lipoprotein lipase. LDL cholesterol was calculated using the Friedewald formula. FBS and HbA1c were measured by using Abbott's Diabetes Care FreeStyle Libre.

Intervention Type

Supplement

Primary outcome measure

- 1. Lipid profile (consisting of total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride concentrations) measured at baseline and after 4 and 8 weeks. Lipid profiles were done after 10 hours of mandatory fasting and FBS was done after 8 hours fast.
- 1.1. Total cholesterol, HDL-cholesterol and triglyceride concentrations measured in serum by a Roch/Hitachi Modular P Chemistry Analyzer (Mod P)
- 1.2. The cholesterol assay used the cholesterol oxidase/peroxidase (CHOD/POD) method
- 1.3. HDL cholesterol was measured by a direct non-precipitating method using polyethylene glycol-coupled cholesteryl esterase (PEG-modified enzyme) and cholesterol oxidase
- 1.4. Triglycerides were analyzed using the glycerokinase/glycerophosphate oxidase method after initial hydrolysis with lipoprotein lipase. LDL cholesterol was calculated using the Friedewald formula.

Secondary outcome measures

Fasting blood sugar (FBS) and HbA1c measured using Abbott's Diabetes Care FreeStyle Libre at baseline, after 4 weeks and 8 weeks

Overall study start date

03/04/2013

Completion date

08/06/2017

Eligibility

Key inclusion criteria

- 1. Healthy volunteers aged 25-60 years
- 2. Total cholesterol level ≤250 mg/dl
- 3. Triglyceride level ≤300 mg/dl
- 4. Not on any form of medication or on nutritional supplementation

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

25 Years

Upper age limit

60 Years

Sex

Both

Target number of participants

200

Total final enrolment

190

Key exclusion criteria

- 1. Total cholesterol level ≥250 mg/dl
- 2. Triglyceride level ≥300 mg/dl
- 3. On any form of medication or nutritional supplementation

Date of first enrolment

01/04/2014

Date of final enrolment

30/06/2014

Locations

Countries of recruitment

Sri Lanka

Study participating centre

Medical Research Institute

PO Box 527, Sir Danister de Silva Mawatha Colombo

Sri Lanka 00900

Sponsor information

Organisation

Medical Research Institute

Sponsor details

PO Box 527

Dr. Danister de Silva Mawatha

Colombo 8

Sri Lanka

00900 +94 (0)112696234 info@mri.gov.lk

Sponsor type

Government

Website

http://www.mri.gov.lk

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in BMC Lipids in Health and Disease

Intention to publish date

30/10/2023

Individual participant data (IPD) sharing plan

- 1. The datasets generated during and/or analysed during the current study will be available upon request from Dr Ruvan Ekanayake (Ruvan_nishali.ekanayaka@yahoo.com).
- 2. The datasets generated during and/or analysed during the current study will be published as a supplement to the results publication

The SPSS data file of the participants contains age, gender, BMI and measurements of lipid profile (consisting of total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride concentrations), Fasting Blood Sugar (FBS) and HbA1c that were done 3 times: i.e., baseline, after 4 weeks and 8 weeks, will be shared. Consent was obtained from all the participants.

IPD sharing plan summary

Available on request, Published as a supplement to the results publication

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results article02/02/202404/10/2024YesNo